Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 10:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 45 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: HAART regimen Clear all
Completed Phase 4 Interventional Results available

Kaletra-isentress Treatment Evaluation

NCT00700115
View directory record Official record
Conditions
HIV Infections
Interventions
Kaletra + Isentress, Pre-study antiretroviral regimen
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 11, 2014 · Synced Sep 23, 2026, 10:42 PM EDT
Completed Not applicable Interventional

Safety and Durability ofTenofovir and a Cell Cycle Agent for Viral Suppression

NCT00344981
View directory record Official record
Conditions
HIV Infections, AIDS
Interventions
Tenofovir, Hydroxyurea
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 10, 2021 · Synced Sep 23, 2026, 10:42 PM EDT
Completed Phase 2 Interventional

Effects of Changing HIV Therapy at Lower Versus Higher Viral Loads

NCT00036465
View directory record Official record
Conditions
HIV Infections
Interventions
Treatment regimen change
Behavioral
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
23
States / cities
Menlo Park, California • Stanford, California • Torrance, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2013 · Synced Sep 23, 2026, 10:42 PM EDT
Completed Phase 4 Interventional Results available

IMPAACT 1077HS: Examining Benefits of HAART Continuation in Postpartum Women

NCT00955968
View directory record Official record
Conditions
HIV Infection
Interventions
Highly active antiretroviral therapy (HAART)
Drug
Lead sponsor
International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Network
Eligibility
18 Years and older · Female only
Enrollment
1,653 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
26
States / cities
Alhambra, California • Los Angeles, California • San Diego, California + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2023 · Synced Sep 23, 2026, 10:42 PM EDT
Terminated Phase 4 Interventional Results available

Evaluation of 3TC or FTC Mono-therapy Compared to Continuing HAART as a Bridging Strategy

NCT01338025
View directory record Official record
Conditions
HIV Disease
Interventions
HAART regimen, 3TC or FTC monotherapy
Drug
Lead sponsor
International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Network
Eligibility
8 Years to 24 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
10
States / cities
San Francisco, California • Washington D.C., District of Columbia • Jacksonville, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2015 · Synced Sep 23, 2026, 10:42 PM EDT
Completed Not applicable Interventional Results available

Preservation and Expansion of T-cell Subsets Following HAART De-intensification to Atazanavir/Ritonavir (ATV/r)

NCT00491556
View directory record Official record
Conditions
HIV Infections
Interventions
Early Initiation of Highly Active Anti-Retroviral Therapy, Standard Care
Procedure
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 24 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
22
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2017 · Synced Sep 23, 2026, 10:42 PM EDT
Completed Phase 4 Interventional

Single Tablet Regimen (STR) Simplification Study for HIV-1 Infected Patients

NCT00365612
View directory record Official record
Conditions
HIV Infections
Interventions
Efavirenz (EFV), Emtricitabine (FTC), Tenofovir DF (TDF)
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 80 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
54
States / cities
Hobson City, Alabama • Phoenix, Arizona • Beverly Hills, California + 50 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2008 · Synced Sep 23, 2026, 10:42 PM EDT
Completed Phase 3 Interventional

Switching HIV-1 Infected Subjects From a Highly Active Anti-Retroviral Treatment (HAART) Regimen Dosed Twice Daily or More Frequently to a Once-Daily Regimen

NCT00135369
View directory record Official record
Conditions
HIV Infections
Interventions
stavudine extended-release, lamivudine, efavirenz
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
46
States / cities
Hobson City, Alabama • Montgomery, Alabama • Phoenix, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2011 · Synced Sep 23, 2026, 10:42 PM EDT
Completed Phase 4 Interventional Results available

Anti-HIV Medications for People Recently Infected With HIV

NCT00106171
View directory record Official record
Conditions
HIV Infections
Interventions
Highly active antiretroviral therapy (HAART)
Drug
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 12, 2023 · Synced Sep 23, 2026, 10:42 PM EDT
Withdrawn Phase 1 Interventional

Gene-Modified HIV-Protected Stem Cell Transplant in Treating Patients With HIV-Associated Lymphoma

NCT02378922
View directory record Official record
Conditions
AIDS-Related Hodgkin Lymphoma, AIDS-Related Non-Hodgkin Lymphoma, HIV Infection, Recurrent Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma
Interventions
Gene-Modified HIV-Protected Hematopoietic Stem Cells, Laboratory Biomarker Analysis, Transplant Conditioning
Biological · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 66 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 26, 2018 · Synced Sep 23, 2026, 10:42 PM EDT
Completed Phase 1 Interventional

Study of KP-1461 for the Treatment of HIV Positive Patients Who Have Failed Multiple HAART Regimens

NCT00129194
View directory record Official record
Conditions
HIV Infections
Interventions
KP-1461
Drug
Lead sponsor
Koronis Pharmaceuticals.
Industry
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
9
States / cities
Bradenton, Florida • Miami, Florida • West Palm Beach, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2008 · Synced Sep 23, 2026, 10:42 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Clinical Trial of CNS-targeted HAART (CIT2)

NCT00624195
View directory record Official record
Conditions
HIV Infections
Interventions
FDA Approved Antiretroviral Therapy (see list below)
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
5
States / cities
San Diego, California • San Francisco, California • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2014 · Synced Sep 23, 2026, 10:42 PM EDT
Completed No phase listed Observational

Effect of the Atazanavir (ATV) 150L Mutation on Subsequent Treatment Response in HIV Infected Subjects

NCT00096746
View directory record Official record
Conditions
HIV Infection
Interventions
LPV/RTV + 2NRTIs
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
13
States / cities
Phoenix, Arizona • Altamonte Springs, Florida • Fort Lauderdale, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2011 · Synced Sep 23, 2026, 10:42 PM EDT
Completed Phase 4 Interventional Results available

A Research Study to See if a Change in Therapy for HIV Infection Can Improve the Immune Response to Treatment

NCT00145795
View directory record Official record
Conditions
HIV Infections
Interventions
Kaletra + Current Dual NRTI Backbone, Current Regimen
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 14, 2022 · Synced Sep 23, 2026, 10:42 PM EDT
Completed Not applicable Interventional

Adding Maraviroc to the HAART Regimen of Well Controlled HIV-infected Patients

NCT02934022
View directory record Official record
Conditions
HIV Infection
Interventions
Maraviroc
Drug
Lead sponsor
Southern California Institute for Research and Education
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Oct 13, 2016 · Synced Sep 23, 2026, 10:42 PM EDT
Terminated Not applicable Interventional

Safety and Effectiveness of 3 Anti-HIV Treatments in Patients Who Have Failed Previous Treatments Containing Nelfinavir

NCT00006326
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Ritonavir, Delavirdine mesylate
Drug
Lead sponsor
Agouron Pharmaceuticals
Industry
Eligibility
0 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 23, 2026, 10:42 PM EDT
Completed Phase 2 Interventional Results available

Effect of Intermittent Aldesleukin Treatment With or Without Anti-HIV Drugs in HIV Infected People

NCT00110812
View directory record Official record
Conditions
HIV Infections
Interventions
IL-2
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
11
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Bethesda, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Sep 23, 2026, 10:42 PM EDT
Completed Phase 3 Interventional

Anti-HIV Drug Regimens With or Without Protease Inhibitors and Drug Level Monitoring in HIV Infected Adolescents

NCT00075907
View directory record Official record
Conditions
HIV Infections
Interventions
Efavirenz + 2 NRTIs, Lopinavir/Ritonavir + 2 NRTIs, Therapeutic Drug Monitoring
Drug · Procedure
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years to 23 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
13
States / cities
Alhambra, California • Long Beach, California • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2013 · Synced Sep 23, 2026, 10:42 PM EDT
Completed Phase 2 Interventional

Study Comparing Racivir and Lamivudine in Treatment-Experienced HIV Subjects

NCT00121979
View directory record Official record
Conditions
HIV Infections
Interventions
Racivir, a non-nucleoside reverse transcriptase inhibitor
Drug
Lead sponsor
Pharmasset
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
3
States / cities
Chicago, Illinois • The Bronx, New York • Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 2, 2007 · Synced Sep 23, 2026, 10:42 PM EDT
Completed Phase 1 Interventional

Sirolimus in Treating Patients With HIV-Related Kaposi's Sarcoma

NCT00450320
View directory record Official record
Conditions
Sarcoma
Interventions
sirolimus
Drug
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
3
States / cities
La Jolla, California • Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 28, 2014 · Synced Sep 23, 2026, 10:42 PM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Adding Enfuvirtide to Oral Highly Active Antiretroviral Therapy (HAART) in Human Immunodeficiency Virus (HIV) Patients With Prior Treatment Experience

NCT00487188
View directory record Official record
Conditions
HIV Infections
Interventions
Enfuvirtide, Highly active antiretroviral treatment (HAART)
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
3
States / cities
Cleveland, Ohio • Austin, Texas • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 12, 2015 · Synced Sep 23, 2026, 10:42 PM EDT
Completed Phase 4 Interventional Results available

Equivalence of Boosted Atazanavir Based Regimens and Currently Effective HAART Regimens

NCT00940771
View directory record Official record
Conditions
Pediatric HIV, HIV Infections
Interventions
Boosted Atazanavir
Drug
Lead sponsor
Phoenix Children's Hospital
Other
Eligibility
6 Years to 18 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 19, 2020 · Synced Sep 23, 2026, 10:42 PM EDT
Completed Phase 2 Interventional

Safety and Effectiveness of Treating HIV-Positive Patients With an HIV Vaccine (Remune)

NCT00005001
View directory record Official record
Conditions
HIV Infections
Interventions
HIV-1 Immunogen
Biological
Lead sponsor
Agouron Pharmaceuticals
Industry
Eligibility
13 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 23, 2026, 10:42 PM EDT
Completed Phase 1 Interventional

Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases SB-728 for HIV

NCT00842634
View directory record Official record
Conditions
HIV, HIV Infections
Interventions
ZFN modified T cells, Structured Treatment Interruption
Biological · Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
2
States / cities
The Bronx, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 7, 2019 · Synced Sep 23, 2026, 10:42 PM EDT